BRPI0508880A - uso de compostos orgánicos - Google Patents

uso de compostos orgánicos

Info

Publication number
BRPI0508880A
BRPI0508880A BRPI0508880-1A BRPI0508880A BRPI0508880A BR PI0508880 A BRPI0508880 A BR PI0508880A BR PI0508880 A BRPI0508880 A BR PI0508880A BR PI0508880 A BRPI0508880 A BR PI0508880A
Authority
BR
Brazil
Prior art keywords
hypertension
disease
restenosis
organic compounds
syndrome
Prior art date
Application number
BRPI0508880-1A
Other languages
English (en)
Inventor
David Louis Feldman
Steven Zelenkofske
Michaela Dinboeck
Margaret Forney Prescott
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0508880A publication Critical patent/BRPI0508880A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"USO DE COMPOSTOS ORGáNICOS". A presente invenção refere-se a um método para prevenir, retardar progressão manifestada ou tratar uma condição ou doença selecionada de diabetes tipo 2 (associada ou não à hipertensão), hipertensão grave, PH, hipertensão maligna, hipertensão sistólica isolada, hipertensão dislipidêmica familial, disfunção endotelial (com ou sem hipertensão), sobrevivência pós-Ml, aumento de formação de colágeno e outras proteínas matrizes celulares, reestenose após colocação de stent, PVD incluindo doença arterial periférica PAD e doenças venosas periféricas, CAD, morbidade, mortalidade, doenças cerebrovasculares, distúrbio metabólico (Síndrome X), AF, renoproteção, redução de proteinúria, insuficiência renal, glomerulonefrite, síndrome nefrótica, fibrose renal, AIN, ATN, nefrite tubulointersticial aguda, PKD, inflamação vascular, tumores secretores de renina, vasculitides ou fechamento, reestenose de enxerto de acesso de diálise, que compreende administrar um composto de fórmula (I) ou um sal farmaceuticamente eficaz deste sozinho ou em combinação com outro ingrediente ativo.
BRPI0508880-1A 2004-03-17 2005-03-16 uso de compostos orgánicos BRPI0508880A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55387704P 2004-03-17 2004-03-17
US55735804P 2004-03-29 2004-03-29
PCT/EP2005/002809 WO2005089731A2 (en) 2004-03-17 2005-03-16 Use of renin inhibitors in therapy

Publications (1)

Publication Number Publication Date
BRPI0508880A true BRPI0508880A (pt) 2007-09-04

Family

ID=34962409

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508880-1A BRPI0508880A (pt) 2004-03-17 2005-03-16 uso de compostos orgánicos

Country Status (15)

Country Link
US (1) US20080161321A1 (pt)
EP (2) EP1977741A3 (pt)
JP (2) JP2007529459A (pt)
KR (1) KR20070006774A (pt)
AU (2) AU2005224014B9 (pt)
BR (1) BRPI0508880A (pt)
CA (1) CA2558020A1 (pt)
IL (2) IL177831A0 (pt)
MA (1) MA28535B1 (pt)
NO (1) NO20064672L (pt)
NZ (2) NZ549535A (pt)
RU (2) RU2426532C2 (pt)
SG (1) SG153831A1 (pt)
TW (1) TW200605867A (pt)
WO (1) WO2005089731A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060416A1 (es) 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion
ITMI20050150A1 (it) 2005-02-03 2006-08-04 Umberto Cornelli Prodotti alimentari
EP1904652A2 (en) 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
RU2008119687A (ru) * 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
US20090005361A1 (en) * 2006-02-06 2009-01-01 Randy Lee Webb Combination of Organic Compounds
ITMI20060384A1 (it) * 2006-03-03 2007-09-04 Umberto Cornelli Composizioni comprendenti chitosano atte al trattamento terapeutico complessivo o alla prevenzione complessiva della sindrome metabolica
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
BRPI0721167A2 (pt) * 2006-12-15 2014-03-18 Novartis Ag Inibidores de renina para prevenção e tratamento de hipertensão em pacientes obesos.
TWI452044B (zh) * 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
CA2697057A1 (en) * 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
AR077428A1 (es) * 2009-07-29 2011-08-24 Sanofi Aventis (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos
CA2780464A1 (en) 2009-10-14 2011-04-21 Rainer Oberbauer Acute kidney injury risk testing
US9573976B2 (en) 2012-09-19 2017-02-21 University Of Utah Research Foundation Antagonist for (pro)renin receptor for the treatment of hypertension and diabetes
US10780143B2 (en) 2012-09-19 2020-09-22 University Of Utah Research Foundation Compositions and methods of use for (pro)renin receptor antagonists
US9586995B2 (en) 2012-09-19 2017-03-07 University Of Utah Research Foundation Compositions and methods of use for (pro)renin receptor
WO2016019226A1 (en) * 2014-08-01 2016-02-04 University Of Utah Research Foundation Compositions and methods of use for (pro)renin receptor antagonists
JP6198047B2 (ja) * 2013-08-02 2017-09-20 国立大学法人岐阜大学 冠動脈疾患の検査キット
US20170014386A1 (en) * 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
RU2742300C2 (ru) * 2015-08-26 2021-02-04 Регьюлэс Терапьютикс Инк. Способы лечения поликистозной болезни почек
WO2017159574A1 (ja) * 2016-03-18 2017-09-21 テルモ株式会社 心機能測定装置、心機能測定方法および心機能測定プログラム
TW202308706A (zh) 2021-04-21 2023-03-01 日商日本醫事物理股份有限公司 放射性抗腫瘤劑
WO2023060237A1 (en) 2021-10-08 2023-04-13 Regulus Therapeutics Inc. Methods and compositions for treatment of polycystic kidney disease

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1962497C3 (de) 1969-12-12 1979-09-20 C.H. Boehringer Sohn, 6507 Ingelheim Naphthylalkyl- a -hydroxyphenäthyl-amine, ihre Herstellung und diese enthaltende Arzneimittel
US3931305A (en) 1973-08-20 1976-01-06 Standard Oil Company Terephthalic acid recovery by continuous flash crystallization
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4885292A (en) * 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
SG52330A1 (en) 1989-06-14 1998-09-28 Smithkline Beecham Corp Imidazolyl-alkenoic acids
US5194605A (en) * 1989-12-08 1993-03-16 Merck & Co., Inc. Cyclic renin inhibitors containing 2-substituted (3S,4S)-4-amino-5-cyclohexyl-3-hydroxy pentanoic acid, 2-substituted (3S,4S)-5-cyclohexyl-3,4-di-hydroxy pentanoic acid or 2-substituted (4S,5S)-5-amino-6-cyclohexyl-4-hydroxyhexanoic acid or its analogs
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
EP0443983B1 (de) 1990-02-19 1996-02-28 Ciba-Geigy Ag Acylverbindungen
TW201738B (pt) 1990-03-20 1993-03-11 Sanofi Co
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5821232A (en) * 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
EP0565634B1 (en) * 1990-12-14 1999-03-17 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
CA2229000C (en) 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
ZA921381B (en) * 1991-03-01 1992-11-25 Fujisawa Pharmaceutical Co New use of amino acid derivatives
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
TW226375B (pt) 1991-10-24 1994-07-11 American Home Prod
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
DK0699069T3 (da) 1993-04-27 2002-05-27 Smithkline Beecham Corp Endothelinreceptorantagonister
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
DK0714897T3 (da) 1993-08-18 2001-03-19 Banyu Pharma Co Ltd Ring-kondenseret heteroaromatisk cyclopentenderivat med endothelinantagonist-aktivitet
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
AU711832B2 (en) 1994-08-19 1999-10-21 Abbvie Bahamas Ltd. Endothelin antagonists
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
TW313568B (pt) 1994-12-20 1997-08-21 Hoffmann La Roche
PL193686B1 (pl) 1995-09-07 2007-03-30 Hoffmann La Roche Pochodne piperydyny, środki lecznicze zawierającepochodne piperydyny, sposoby wytwarzania tych pochodnych oraz zastosowanie pochodnych
KR100456650B1 (ko) 1995-12-20 2005-06-20 야마노우치세이야쿠 가부시키가이샤 아릴에텐설폰아미드유도체
IT1277737B1 (it) 1995-12-28 1997-11-12 Zambon Spa Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
WO1997027314A1 (fr) 1996-01-23 1997-07-31 Shionogi & Co., Ltd. Processus de production d'analogues d'acide oleanolique par la culture de racine pileuse
EE9800315A (et) 1996-04-04 1999-06-15 Banyu Pharmaceutical Co., Ltd. Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
DK1216038T3 (da) * 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
FR2801538B1 (fr) * 1999-11-30 2002-01-11 France Design Systeme de toit rigide escamotable pour structure decouvrable, notamment pour vehicule
US20030187038A1 (en) * 2000-08-25 2003-10-02 Yoshimi Imura Fibrinogen-lowering agents
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
CN1571668A (zh) * 2001-10-18 2005-01-26 诺瓦提斯公司 At1－受体拮抗剂和心血管药物形成的盐
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
KR20100137026A (ko) * 2002-05-17 2010-12-29 노파르티스 아게 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
US20030229007A1 (en) * 2002-05-30 2003-12-11 Roberto Levi Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
MXPA04012136A (es) * 2002-06-27 2005-04-19 Actelion Pharmaceuticals Ltd Nuevos derivados de tetrahidropiridina como inhibidores de renina.
AU2003250858A1 (en) * 2002-06-28 2004-01-19 Novartis Ag Use of organic compounds
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
AU2004270161A1 (en) * 2003-08-28 2005-03-17 Nicox S.A. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
US20070135406A1 (en) * 2003-12-05 2007-06-14 Olivier Bezencon Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain
BRPI0507030A (pt) * 2004-01-22 2007-06-05 Novartis Ag combinação de compostos orgánicos
TW200538154A (en) * 2004-02-17 2005-12-01 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
JP2011178799A (ja) 2011-09-15
AU2005224014B2 (en) 2009-07-16
RU2006136091A (ru) 2008-04-27
KR20070006774A (ko) 2007-01-11
JP2007529459A (ja) 2007-10-25
NO20064672L (no) 2006-12-14
WO2005089731A3 (en) 2006-05-11
MA28535B1 (fr) 2007-04-03
RU2426532C2 (ru) 2011-08-20
AU2005224014B9 (en) 2009-08-27
CA2558020A1 (en) 2005-09-29
SG153831A1 (en) 2009-07-29
TW200605867A (en) 2006-02-16
EP1729749A2 (en) 2006-12-13
AU2009222444A1 (en) 2009-10-15
RU2010149052A (ru) 2012-06-10
WO2005089731A2 (en) 2005-09-29
IL177831A0 (en) 2006-12-31
AU2005224014A1 (en) 2005-09-29
NZ549535A (en) 2010-11-26
IL209964A0 (en) 2011-02-28
NZ586285A (en) 2011-12-22
EP1977741A2 (en) 2008-10-08
EP1977741A3 (en) 2009-10-14
US20080161321A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
TW200605867A (en) Use of organic compounds
Davies et al. NO‐naproxen vs. naproxen: ulcerogenic, analgesic and anti‐inflammatory effects
Kellum Systematic review: The use of diuretics and dopamine in acute renal failure: a systematic review of the evidence
Angulo et al. Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF
BRPI0413028A (pt) composto, uso de um composto, composição farmacêutica, e, kit farmacêutico
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
WO2007126964A3 (en) Kinase inhibitors
ECSP055525A (es) Inhibidores de cinasas de tirosina
BR0109966A (pt) Combinação de compostos orgânicos
Luetic et al. Cyclophosphamide induced stomach and duodenal lesions as a NO-system disturbance in rats: L-NAME, L-arginine, stable gastric pentadecapeptide BPC 157
Sica et al. Type 2 diabetes: RENAAL and IDNT—the emergence of new treatment options
UY26926A1 (es) Derivados de la quinolina y quinazolina
AR065092A1 (es) TERAPIA DE COMBINACIoN CON INHIBIDORES DE LA ANGIOGÉNESIS
AR052221A1 (es) Metodo para el tratamiento de la enfermedad poliquistosis renal
WO2006007378A3 (en) Pyrrolotriazine kinase inhibitors
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
Perazella COX-2 selective inhibitors: analysis of the renal effects
CA2481767A1 (en) Severe sepsis preventive therapeutic agent
Contreras et al. Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension
Soler et al. Angiotensin‐converting enzyme 2 and the kidney
WO2005121778A3 (en) Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
Karnad et al. Calcium enhances antiinflammatory activity of aspirin in albino rats
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
BR0312712A (pt) Aminoácido modificado para a inibição da agregação plaquetária

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.